8-K: MaxCyte Reports Q4/FY25 Results, Guides Lower for 2026

MaxCyte announced its fourth quarter and full year 2025 financial results, reporting revenue at the top of its preliminary range but providing lower revenue guidance for 2026 due to customer headwinds.

Summary

• Total revenue for Q4 2025 was $7.3 million, a 16% decrease from Q4 2024.
• Full year 2025 total revenue was $33.0 million, a 15% decrease from full year 2024.
• Core business revenue for Q4 2025 was $6.8 million (down 22% from Q4 2024) and for full year 2025 was $29.6 million (down 9% from full year 2024).
• Strategic Platform License (SPL) Program-related revenue was $0.5 million in Q4 2025 (up from $0.1 million in Q4 2024) and $3.4 million for full year 2025 (down from $6.1 million in full year 2024).
• Ended 2025 with 32 SPL agreements, including 13 programs in the clinic and one commercial program.
• Total cash, cash equivalents, and investments were $155.6 million as of December 31, 2025.
• Full year 2026 revenue guidance is $30 million to $32 million, with Core revenue of $25 million to $27 million and SPL Program-related revenue of approximately $5 million.
• Expects to end 2026 with at least $136 million in total cash, cash equivalents, and investments.
• Experienced headwinds from select SPL customers, including a 15% reduction in purchases and leases from its largest customer, which impacted 2025 revenues.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While 2025 results met the high end of preliminary expectations and cost controls are evident, the 2026 guidance reflects ongoing customer headwinds and a projected revenue decline, tempering enthusiasm despite new product launches and pipeline expansion.

Positives

• Fourth quarter and full year 2025 total revenue of $7.3 million and $33.0 million, respectively, were at the top of the range of previous preliminary announcements.
• Reduced annual cash burn by more than $16 million in 2025.
• Streamlined cost structure in 2025.
• Advanced new product launches, including the ExPERT DTx discovery platform launched in Q1 2026.
• Expanded SPL portfolio by signing 4 new SPLs in 2025, bringing the total to 32 agreements.
• Expects to support up to four therapies in Phase III by the end of 2026 and has already received a milestone payment for one of these therapies.
• Gross profit margin for Q4 2025 improved to 78% from 74% in Q4 2024.
• Operating expenses for Q4 2025 decreased to $16.9 million from $19.3 million in Q4 2024.
• Net loss for Q4 2025 decreased to $9.6 million from $10.6 million in Q4 2024.
• EBITDA loss for Q4 2025 decreased to $10.2 million from $11.8 million in Q4 2024.
• Total cash, cash equivalents and investments of $155.6 million as of December 31, 2025, provides a healthy balance sheet.

Negatives

• Total revenue decreased by 16% in Q4 2025 ($7.3 million) compared to Q4 2024 ($8.7 million).
• Total revenue decreased by 15% for full year 2025 ($33.0 million) compared to full year 2024 ($38.6 million).
• Core business revenue decreased by 22% in Q4 2025 and 9% for full year 2025.
• SPL Program-related revenue decreased by 44% for full year 2025 ($3.4 million) compared to full year 2024 ($6.1 million).
• Experienced headwinds from select SPL customers, including a 15% reduction in purchases and leases from its largest customer, which impacted 2025 revenues.
• 2026 total revenue guidance of $30-32 million is lower than 2025 actual revenue of $33.0 million.
• 2026 core revenue guidance of $25-27 million includes approximately $4 million in core revenue headwind from select SPL customers.
• Total number of licensed clinical programs under SPLs currently in the clinic decreased to 13 as of December 31, 2025, from 18 as of December 31, 2024.
• Full year 2025 net loss increased to $44.6 million compared to $41.1 million in 2024.
• Full year 2025 EBITDA loss increased to $47.6 million compared to $46.9 million in 2024.
• Total cash, cash equivalents and investments decreased to $155.6 million as of December 31, 2025, from $190.3 million as of December 31, 2024.

Risks

• Headwinds from select Strategic Platform License (SPL) customers, including a 15% reduction in purchases and leases from the largest customer, which impacted 2025 revenues and is expected to stabilize in the second half of 2026.
• The inherent uncertainties and assumptions associated with forward-looking statements, which may cause actual results to differ materially from projections.
• General market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to current and potential partners.
• Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) in next-generation cell therapy programs.
• Lack of industry standard for cell engineering process development causes costly and inconsistent manufacturing runs.
• Many steps in the cell engineering process with lack of support or safety assessments before regulatory review.

Future Outlook

MaxCyte expects full year 2026 revenue to be between $30 million and $32 million, comprising $25 million to $27 million from Core revenue and approximately $5 million from SPL Program-related revenue (including $3 million from milestones and $2 million from commercial royalties). The company anticipates ending 2026 with at least $136 million in total cash, cash equivalents, and investments. Management believes it will be supporting up to four therapies in Phase III by the end of 2026 and expects headwinds from select SPL customers to stabilize and grow from the new base in the second half of 2026. MaxCyte also plans to focus on growing its sales pipeline across its ExPERT electroporation platform and SeQure assay services business units, including driving growth in the newly launched ExPERT DTx discovery platform.

Management Comments

• "Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base."
• "Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte's position in the growing cell and gene therapy market for the long term."
• "We also continued to expand our SPL portfolio, by signing 4 new SPLs in 2025."
• "As we look ahead to 2026, we will focus on growing our sales pipeline across our ExPERT electroporation platform and SeQure assay services business units, including driving growth in our new ExPERT DTx discovery platform which launched last month."
• "Our 2026 total revenue guidance calls for $30-32 million, which we believe is appropriate as it includes approximately $4 million in core revenue headwind from select SPL customers, which began to impact revenue in the second half of 2025."
• "I remain more excited than ever in the future growth of our company. I believe we now will be supporting up to four therapies in Phase III by the end of 2026 and have already received a milestone payment for one of these therapies."
• "The expansion of CGT, including ongoing clinical progress, which we are part of, underpins the long-term opportunity for MaxCyte."

Industry Context

StockSavvy.ai notes that the cell and gene therapy market continues to be a rapidly growing and promising treatment modality, with approximately 2,130 active clinical trials as of December 2025 and an aggregate of $11.1 billion raised in 2025. MaxCyte's focus on enabling non-viral cell engineering positions it within a significant segment of this market, with 66% of preclinical programs and 50% of clinical programs being non-viral. The company's platform addresses critical challenges in cell and gene therapy development, such as the complexity of next-generation programs, regulatory risks, and the need for faster manufacturing times.

Comparison to Industry Standards

• MaxCyte's platform supports a diverse portfolio of product candidates, including the recently approved CASGEVY (Vertex Pharmaceuticals/CRISPR Therapeutics) for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. This commercial success demonstrates the real-world application and regulatory acceptance of MaxCyte's technology in a leading gene-edited cell therapy.
• The company's 32 SPL agreements and 13 clinical programs (including 1 commercial program) indicate a strong integration into the R&D pipelines of biopharmaceutical companies, comparable to other platform technology providers that embed their solutions early in the drug development process.
• The "razor/razor blade" economic model, combining instrument sales/leases with recurring disposables and milestone/royalty payments, aligns with successful strategies seen in other life science tool companies that capture value throughout the drug lifecycle.
• The decrease in licensed clinical programs from 18 to 13 year-over-year, while new SPLs were signed, suggests a dynamic pipeline where some programs may have been discontinued or advanced, which is a common occurrence in the high-risk, high-reward cell and gene therapy development landscape.

Stakeholder Impact

• Shareholders: Impacted by declining revenue, increased net losses, and lower 2026 guidance, but also by efforts to reduce cash burn and expand the product portfolio for long-term growth.
• Customers: Benefit from new product launches like ExPERT DTx, expanded SPL portfolio, and continued scientific, technical, and regulatory support for cell engineering.
• Employees: Affected by the streamlining of the cost structure, which could imply workforce adjustments, but also by investment in new product development.
• Creditors: The healthy cash balance of $155.6 million (expected to be at least $136 million by end of 2026) suggests strong liquidity, positively impacting creditors.

Next Steps

• Focus on growing the sales pipeline across ExPERT electroporation platform and SeQure assay services business units.
• Drive growth in the new ExPERT DTx discovery platform.
• Expect stabilization and growth from select SPL customers in the second half of 2026.
• Host a conference call on March 24, 2026, at 4:30 p.m. Eastern Time.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, on or about March 25, 2026.

Key Dates

Recommendation

MaxCyte's 2025 results, while showing revenue decline, met the high end of preliminary expectations, and the company demonstrated effective cost control by reducing cash burn. The expansion of the SPL portfolio and new product launches like ExPERT DTx are positive long-term indicators. However, the lower 2026 revenue guidance, driven by persistent customer headwinds, suggests near-term challenges and uncertainty. The decrease in active clinical programs under SPLs is also a concern. Given the mixed signals—strategic progress and cost management against revenue contraction and a cautious outlook—a "hold" recommendation is appropriate. Investors should monitor the stabilization of customer headwinds and the uptake of new platforms in the latter half of 2026 before making further investment decisions.

Keywords

MaxCyte, MXCT, cell engineering, gene therapy, cell therapy, electroporation, ExPERT platform, SeQure assay services, financial results, revenue guidance, SPL agreements, clinical programs, biotechnology, life sciences, Q4 2025, FY 2025, FY 2026